Efficacy and safety of sitafloxacin (STFX) in tonsillar abcess; prospective study in outpatient setting.

Efficacy and safety of sitafloxacin (STFX) in tonsillar abcess; prospective study in outpatient setting. - Efficacy and safety of sitafloxacin in tonsillar abcess.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013812

Enrollment

Registered

2014-04-25

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritonsillar abcess

Interventions

200mg/day of sitafloxacin for 1-2weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who diagnosed peritonsillar abcess.

Exclusion criteria

Exclusion criteria: Patients who need hospitalization Allergy for sitafloxacin pregnant or probable pregnant renal dysfunction (Ccr<50) airway stenosis

Design outcomes

Primary

Measure	Time frame
subjective symptom, objective findings, CRP, WBC	—

Secondary

Measure	Time frame
adverse events	—

Countries

Japan

Contacts

Public ContactAtsushi Kamijo

Saitama Medical University Otorhinolaryngology

atkamijo@saitama-med.ac.jp049-276-1253

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026